title: High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins.
abstract: Hepatocellular carcinoma (HCC) is an especially frequent malignancy in China. Radiofrequency ablation, percutaneous ethanol injection, transarterial chemoembolization, cryoablation, microwave coagulation, and laser-induced interstitial thermotherapy all offer potential local tumor control and occasionally achieve long-term disease-free survival. High-intensity focused ultrasound (HIFU), as a noninvasive therapy, can be applied to treat tumors that are difficult to treat with other techniques. The preliminary results of HIFU in clinical studies are encouraging. The aims of this investigation were to assess the efficacy of the system in obtaining necrosis of the target tissue and to determine whether HIFU ablation is hazardous to adjacent major blood vessels. Over 7 years, thirty-nine patients with HCC were enrolled in this investigation. The inferior vena cava (IVC), main hepatic vein branches, and the portal vein and its main branches were evaluated. The distance between tumor and main blood vessel was less than 1 cm in all these enrolled patients. Contrast-enhanced MRI was used to evaluate the perfusion of tumors and major blood vessels. We conducted HIFU ablation for the treatment of 39 patients with 42 tumors, with each tumor measuring 7.4+/-4.3 (1.5-22) cm in its greatest dimension. Among the 39 patients, 23 were males and 16 females. The average age was 53.2 years (range 25-77 years). Thirty-seven patients had a solitary lesion, one had two lesions, and the remaining one had three lesions. Nineteen lesions were located in the right lobe of liver, 18 in the left lobe, and 5 in both right and left lobes. Among the 42 tumors, 25 were adjacent to 1 blood vessel, 12 adjacent to 2 main vessels, 2 adjacent to 3 main vessels, and 1 adjacent to 4 main vessels. Twenty-one of the 42 tumors were completely ablated, while the rest of the tumors were ablated by more than 50% of lesion volume after one session of HIFU. No major blood vessel injury was observed in any subject after 23.8+/-17.2 months follow-up. HIFU can achieve complete tumor necrosis even when the lesion is located adjacent to the major hepatic blood vessels. Short-term and long-term follow-up results show that HIFU can be safely used to ablate the tumors adjacent to major vessels.
authors.affiliation: Clinical Center for Tumor Therapy, Second Hospital of Chongqing University of Medical Sciences, 74 Linjiang Road, Chongqing, 400010, People's Republic of China.
authors.forename: Lian
authors.initials: L
authors.lastname: Zhang
authors.forename: Hui
authors.initials: H
authors.lastname: Zhu
authors.forename: Chengbin
authors.initials: C
authors.lastname: Jin
authors.forename: Kun
authors.initials: K
authors.lastname: Zhou
authors.forename: Kequan
authors.initials: K
authors.lastname: Li
authors.forename: Haibing
authors.initials: H
authors.lastname: Su
authors.forename: Wenzhi
authors.initials: W
authors.lastname: Chen
authors.forename: Jin
authors.initials: J
authors.lastname: Bai
authors.forename: Zhibiao
authors.initials: Z
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging* / Q000628:therapy*; D003287:Contrast Media / Q000494:pharmacology; D018450:Disease Progression; D005260:Female; D006503:Hepatic Veins / Q000000981:diagnostic imaging* / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome; D014464:Ultrasonic Therapy / Q000379:methods*; D014463:Ultrasonography
chemical_list: D003287:Contrast Media
references.citation: Radiology. 2000 Mar;214(3):769-74
references.pmid: 10715044
references.citation: Ultrason Sonochem. 2004 May;11(3-4):149-54
references.pmid: 15081972
references.citation: Lancet. 1999 May 15;353(9165):1676-7
references.pmid: 10335793
references.citation: Hepatology. 1998 Jun;27(6):1578-83
references.pmid: 9620330
references.citation: Hepatology. 2000 Dec;32(6):1224-9
references.pmid: 11093728
references.citation: Ann Surg. 1998 Apr;227(4):559-65
references.pmid: 9563546
references.citation: Radiology. 2005 Mar;234(3):961-7
references.pmid: 15665226
references.citation: CA Cancer J Clin. 1995 Jan-Feb;45(1):8-30
references.pmid: 7528632
references.citation: J Gen Physiol. 1942 Nov 20;26(2):179-93
references.pmid: 19873337
references.citation: Ultrasound Med Biol. 2004 Sep;30(9):1217-22
references.pmid: 15550325
references.citation: Radiology. 2005 May;235(2):659-67
references.pmid: 15858105
references.citation: AJR Am J Roentgenol. 1993 Nov;161(5):1065-9
references.pmid: 8273612
references.citation: J Gastroenterol Hepatol. 2008 Mar;23(3):482-90
references.pmid: 18086115
references.citation: Br J Surg. 2004 May;91(5):632-9
references.pmid: 15122617
references.citation: Semin Surg Oncol. 1993 Jul-Aug;9(4):298-304
references.pmid: 8210909
references.citation: Eur Radiol. 2006 Sep;16(9):1990-9
references.pmid: 16541225
references.citation: Ann Surg Oncol. 2004 Dec;11(12):1061-9
references.pmid: 15545506
references.citation: J Neurosurg. 1954 Sep;11(5):471-8
references.pmid: 13201985
references.citation: J Hepatol. 1998 Jul;29(1):129-34
references.pmid: 9696501
references.citation: Gastroenterology. 2006 Aug;131(2):461-9
references.pmid: 16890600
references.citation: Ann Surg Oncol. 2007 May;14(5):1540-50
references.pmid: 17318277
references.citation: J Gastroenterol. 2003;38(10):977-81
references.pmid: 14614605